|
gptkbp:instanceOf
|
HIV prevention method
|
|
gptkbp:administeredBy
|
oral medication
|
|
gptkbp:alternativeTo
|
long-acting injectable (Apretude)
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:commonDrug
|
gptkb:Descovy
gptkb:Truvada
|
|
gptkbp:compatibleWith
|
people already living with HIV
|
|
gptkbp:coveredBy
|
many health insurance plans
|
|
gptkbp:effect
|
over 90% when taken daily
|
|
gptkbp:form
|
once daily
|
|
gptkbp:guidelinesBy
|
gptkb:Centers_for_Disease_Control_and_Prevention
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PrEP
|
|
gptkbp:notProtectAgainst
|
other sexually transmitted infections
|
|
gptkbp:recommendation
|
people at high risk of HIV
|
|
gptkbp:requires
|
prescription
regular HIV testing
|
|
gptkbp:sideEffect
|
nausea
headache
weight loss
|
|
gptkbp:standsFor
|
gptkb:Pre-Exposure_Prophylaxis
|
|
gptkbp:studiedIn
|
gptkb:iPrEx_trial
|
|
gptkbp:takenBy
|
gptkb:men_who_have_sex_with_men
people who inject drugs
heterosexual men and women
|
|
gptkbp:usedFor
|
reducing risk of HIV infection
|
|
gptkbp:WHORecommendation
|
2015
|
|
gptkbp:bfsParent
|
gptkb:pre-exposure_prophylaxis_(PrEP)
gptkb:HIV/AIDS_crisis
gptkb:HIV
|
|
gptkbp:bfsLayer
|
5
|